International. Intarcon, a Spanish manufacturer of compact refrigeration and industrial refrigeration equipment belonging to the Keyter-Intarcon-Genaq industrial group, announced that it has the capacity to produce equipment that allows maintaining the cold chain at a temperature above -80o, after learning the news of the early commercialization of the vaccine against SARS-CoV-2 whose special maintenance needs require conservation at the aforementioned temperature.
In this sense, Intarcon has the most advanced technology in refrigeration using ecological and natural refrigerants. Therefore, it can meet the conservation needs of vaccines such as the one studied by the firm Pfizer and of which the Ministry of Health has announced the acquisition of 20 million doses. The Intarcon equipment, whose production has been developed for a long time, would allow both the conservation of the vaccine and the transfer of it, these being the two most relevant challenges facing the drug, in addition to its storage in an area that is protected from heat and light.
To date, Intarcon has supplied equipment for the conservation of medicines and vaccines in the main hospitals of our country, such as the La Paz University Hospital in Madrid, the Bellvitge University Hospital in Hospitalet de Llobregat or the Vinaròs Regional Hospital in Castellón. Likewise, it is a supplier of refrigeration products for military and civil pharmacies, as well as for the chemical industry that produces generic assets for pharmaceutical products.
In the words of Aurelio García, president of the Keyter-Intarcon-Genaq group, "technological research in our group is a key factor, due to the sectors we are targeting that require a product adapted to the needs of the project, respectful of the environment through energy efficiency and ecological refrigerant gases and with cutting-edge technology that large manufacturers of standard products do not require".
